tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

BCAX Stock Latest News

Bicara Therapeutics Elects New Directors at Annual Meeting
Company AnnouncementsBicara Therapeutics Elects New Directors at Annual Meeting
2M ago
8K
BCAX
Bicara Therapeutics Expands Boston Headquarters with New Lease
PremiumCompany Announcements
Bicara Therapeutics Expands Boston Headquarters with New Lease
2M ago
8K
BCAX
Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa: Analyst Reiterates Buy Rating with Strong Clinical Results and $41 Price Target
PremiumRatings
Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa: Analyst Reiterates Buy Rating with Strong Clinical Results and $41 Price Target
2M ago
BCAX
Promising Efficacy of Bicara Therapeutics’ Ficera in Combination with Pembro for HPV-Negative HNSCC Justifies Buy Rating
PremiumRatings
Promising Efficacy of Bicara Therapeutics’ Ficera in Combination with Pembro for HPV-Negative HNSCC Justifies Buy Rating
2M ago
BCAX
Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
PremiumMarket News
Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
2M ago
ADI
BAH
Wells upgrades Bicara to Equal Weight with thesis played out
PremiumThe FlyWells upgrades Bicara to Equal Weight with thesis played out
2M ago
BCAX
Bicara Therapeutics upgraded to Equal Weight from Underweight at Wells Fargo
Premium
The Fly
Bicara Therapeutics upgraded to Equal Weight from Underweight at Wells Fargo
2M ago
BCAX
Stocks slide as Trump threatens new tariffs against EU and Apple: Morning Buzz
Premium
The Fly
Stocks slide as Trump threatens new tariffs against EU and Apple: Morning Buzz
2M ago
X
BAH
Why Is Bicara Therapeutics Stock (BCAX) Down 30% Today?
PremiumMarket News
Why Is Bicara Therapeutics Stock (BCAX) Down 30% Today?
2M ago
BCAX
Promising Efficacy and Survival Data Drive Buy Rating for Bicara Therapeutics
PremiumRatings
Promising Efficacy and Survival Data Drive Buy Rating for Bicara Therapeutics
2M ago
BCAX
Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa in HPV-Negative HNSCC Drives Buy Rating
PremiumRatings
Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa in HPV-Negative HNSCC Drives Buy Rating
2M ago
BCAX
Closing Bell Movers: Deckers falls 15% on weak guidance; Nuclear names rally
PremiumThe Fly
Closing Bell Movers: Deckers falls 15% on weak guidance; Nuclear names rally
2M ago
NNE
SMR
Bicara Therapeutics publishes updated data from Phase 1/1b trial of Ficerafusp
PremiumThe FlyBicara Therapeutics publishes updated data from Phase 1/1b trial of Ficerafusp
2M ago
BCAX
Bicara Therapeutics Inc.: Promising Clinical Trials and Stable Financial Outlook Support Buy Rating
Premium
Ratings
Bicara Therapeutics Inc.: Promising Clinical Trials and Stable Financial Outlook Support Buy Rating
3M ago
BCAX
Bicara Therapeutics price target lowered to $41 from $44 at H.C. Wainwright
Premium
The Fly
Bicara Therapeutics price target lowered to $41 from $44 at H.C. Wainwright
3M ago
BCAX
Cautious Outlook on Bicara Therapeutics Inc. Amid Uncertain Pipeline and Market Underperformance
PremiumRatings
Cautious Outlook on Bicara Therapeutics Inc. Amid Uncertain Pipeline and Market Underperformance
3M ago
BCAX
Bicara Therapeutics Reports Q1 2025 Financial Results
PremiumCompany Announcements
Bicara Therapeutics Reports Q1 2025 Financial Results
3M ago
BCAX
Promising Clinical Progress and Strategic Expansion Drive Buy Rating for Bicara Therapeutics
PremiumRatings
Promising Clinical Progress and Strategic Expansion Drive Buy Rating for Bicara Therapeutics
3M ago
BCAX
Promising Potential of Bicara Therapeutics’ Ficera: A Buy Rating Backed by Strong Clinical Data and Innovative Approach
PremiumRatings
Promising Potential of Bicara Therapeutics’ Ficera: A Buy Rating Backed by Strong Clinical Data and Innovative Approach
3M ago
BCAX
Bicara Therapeutics reports Q1 EPS (68c), consensus (40c)
PremiumThe FlyBicara Therapeutics reports Q1 EPS (68c), consensus (40c)
3M ago
BCAX
Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa Drives Buy Rating Amid Encouraging Clinical Data and Growth Opportunities
Premium
Ratings
Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa Drives Buy Rating Amid Encouraging Clinical Data and Growth Opportunities
3M ago
BCAX
Cautious Outlook on Bicara Therapeutics Inc. Amid Efficacy and Safety Concerns for Ficerafusp
Premium
Ratings
Cautious Outlook on Bicara Therapeutics Inc. Amid Efficacy and Safety Concerns for Ficerafusp
3M ago
BCAX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >